Compare BioNTech SE - ADR (BNTX) vs Newmont Corporation (NEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Newmont Corporation — how do they compare? BioNTech SE - ADR trades at $89.89 (market cap $22.86B), while Newmont Corporation trades at $94 (market cap $101.15B). The key difference: Newmont Corporation is far larger — about 4.4× BioNTech SE - ADR's market cap, and Newmont Corporation pays a 1.1% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | NEM | |
|---|---|---|
Market Cap | $22.86B | $101.15B |
Sector | Health | Basic Materials |
52-Week High | $119.34 | $131.95 |
52-Week Low | $83.89 | $57.35 |
Enterprise Value | $6.53B | $97.90B |
Dividend Yield | — | 1.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.
The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.
Newmont (NEM) trades at $93.10, down 2.3% over the past day amid a bearish technical signal. The stock shows strong fundamentals with a P/E of 12.08, net income margin of 33.87%, and three consecutive quarterly earnings beats. Recent news highlights Wall Street's positive valuation view despite near-term cost pressures. Cash flow trends are robust, with operating cash flow rising to $10.33 billion in 2025.
Outlook remains favorable given analyst consensus of a $140.11 price target and 75% buy ratings. Key risks include higher unit costs impacting 2026 margins and gold price volatility. The stock offers value with solid profitability and growth, though investors should monitor cost management and gold market dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Newmont Corporation
Newmont Corp is primarily a gold producer with operations and/or assets in the United States, Canada, Mexico, Dominican Republic, Peru, Suriname, Argentina, Chile, Australia, and Ghana. It is also engaged in the production of copper, silver, lead and zinc. The company's operations are organized in five geographic regions: North America, South America, Australia, Africa and Nevada.
Read more on NEM →
